Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)
NCT ID: NCT02875652
Last Updated: 2024-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
800 participants
INTERVENTIONAL
2013-03-21
2019-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
NCT01334008
ctDNA for Early Detection of Recurrence in Melanoma
NCT06246227
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
NCT00897624
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
NCT05736523
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
NCT02220556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patient will have a blood sample at the following times :
* T0: before treatment of the primary tumor.
* T1: 1 months after the end of the local treatment.
* T2: at 7 months.
* Tn: every 6 months up to 3 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood sampling
Blood sampling
3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a recent choroidal melanoma before the start of the specific treatment.
* Patient able to stand a blood collection.
* Work-up for extension (CT).
* Patient explanation given and consent information signed or by legal representative
Exclusion Criteria
* Person deprived of liberty or under guardianship.
* Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Curie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence Desjardins, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Curie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Curie
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC 2012-08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.